Current Meeting     Our Mission     Future & Past Programs      Sponsorship     Board of Directors     Contact Us
Meeting Announcement
Register  Map
Date: Wednesday, May 30th, 2012
Topic: "Beating the Odds: The Journey of an Erythropoiesis Stimulating Agent from Bench to Bedside"
Speaker: Anne-Marie Duliege, M.D.
 Chief Medical Officer
 Affymax
Location:

The Holiday Inn
275 S Airport Blvd
South San Francisco, CA 94080
650-873-3550 | Map
Next door to the SSF Conference Center
Directions at www.hisfo.com

Price:

$45 before 9PM, Monday, May 28th
$55 on-site
$35 full-time students pre-registration
$45 full-time students on-site
$3 service fees will be added to the pre-registration prices

6:00 PM - networking
7:00 PM - dinner
8:00 PM - presentation

Abstract:

In March 2012, Palo Alto based Affymax received FDA approval for OMONTYS® (peginesatide) Injection, a product for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. It is the first Erythropoiesis Stimulating Agent (ESA), dosed once monthly, on the US market. Its drug development journey started with the rigorous selection of an erythropoiesis stimulating peptide with prolonged duration of action, and advanced through an odyssey of extensive preclinical and clinical testing.

In parallel with the drug development challenges, the company went public and entered into a worldwide development and commercialization partnership with Takeda Pharmaceutical. The regulatory environment also evolved due to increasing safety concerns about the ESA class. Yet, in spite of these developments and challenging Phase 3 results, Affymax successfully completed NDA review and received approval of OMONTYS® within the 10-month PDUFA timeline, positioning the company for its first commercial launch. The lessons learned in this "David vs. Goliath story" will address the importance of quality science, focus, transparency, and persistence.

Biography:

Dr. Duliege has over 20 years of scientific and leadership experience in the pharmaceutical industry. She joined Affymax in 2004 as VP of Clinical, Regulatory and Medical Affairs. She was instrumental in raising capital and taking the company public. Dr. Duliege was promoted to Chief Medical Officer in 2007. She lead her team through an extensive development program and obtained FDA approval for the company’s lead product, OMONTYS®. As a member of the executive team, Dr. Duliege is responsible for both clinical and non-clinical research. She helps set company strategies, contributes to investor relations, and supports business development activities.

Prior to joining Affymax, Dr. Duliege was a Senior Medical Director at Chiron Corporation where she directed Phase 1 through 4 clinical studies in pulmonary medicine, infectious disease and immunology. She has also been a Senior Research Physician at Genentech, Inc., working on an HIV treatment and vaccine, and an Epidemiologist at the National Institute of Science & Medical Research in Paris.

Dr. Duliege received her MD degree and her certification in Pediatrics from Paris Medical School. She also has an M.S. in Epidemiology from Harvard School of Public Health and an M.S. in Biostatistics from Paris Medical School. She continues to practice medicine as an Adjunct Clinical Assistant Professor at Stanford’s School of Medicine and Lucile Packard Children’s Hospital. She serves on the board of non-profit organizations focused on the prevention of HIV. She is personally committed to supporting public health efforts in developing countries.

Registration Policy    Registration via CEvent

Platinum Sponsors

Novartis
Pii

Gold Sponsors

Patheon
PPS
ChanTest
Deloitte
RHS Financial

Silver Sponsor

WAVSIP
© BioSF.org ALL RIGHTS RESERVED BioScience Forum